nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—osteoporosis—ankylosing spondylitis	0.928	1	CtDrD
Ibandronate—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.000121	0.00168	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.00012	0.00166	CcSEcCtD
Ibandronate—Shock—Prednisolone—ankylosing spondylitis	0.000119	0.00165	CcSEcCtD
Ibandronate—Hypertension—Triamcinolone—ankylosing spondylitis	0.000117	0.00163	CcSEcCtD
Ibandronate—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000117	0.00163	CcSEcCtD
Ibandronate—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000117	0.00162	CcSEcCtD
Ibandronate—Myalgia—Triamcinolone—ankylosing spondylitis	0.000116	0.00161	CcSEcCtD
Ibandronate—Pneumonia—Methotrexate—ankylosing spondylitis	0.000115	0.0016	CcSEcCtD
Ibandronate—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000115	0.0016	CcSEcCtD
Ibandronate—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000115	0.0016	CcSEcCtD
Ibandronate—Eye disorder—Prednisone—ankylosing spondylitis	0.000115	0.0016	CcSEcCtD
Ibandronate—Anxiety—Methylprednisolone—ankylosing spondylitis	0.000115	0.0016	CcSEcCtD
Ibandronate—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000115	0.0016	CcSEcCtD
Ibandronate—Infestation—Methotrexate—ankylosing spondylitis	0.000115	0.0016	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000115	0.00159	CcSEcCtD
Ibandronate—Depression—Methotrexate—ankylosing spondylitis	0.000114	0.00159	CcSEcCtD
Ibandronate—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.000114	0.00159	CcSEcCtD
Ibandronate—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.000114	0.00159	CcSEcCtD
Ibandronate—Discomfort—Triamcinolone—ankylosing spondylitis	0.000114	0.00159	CcSEcCtD
Ibandronate—Discomfort—Methylprednisolone—ankylosing spondylitis	0.000114	0.00158	CcSEcCtD
Ibandronate—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000113	0.00157	CcSEcCtD
Ibandronate—Renal failure—Methotrexate—ankylosing spondylitis	0.000113	0.00157	CcSEcCtD
Ibandronate—Angioedema—Betamethasone—ankylosing spondylitis	0.000113	0.00157	CcSEcCtD
Ibandronate—Angioedema—Dexamethasone—ankylosing spondylitis	0.000113	0.00157	CcSEcCtD
Ibandronate—Stomatitis—Methotrexate—ankylosing spondylitis	0.000112	0.00155	CcSEcCtD
Ibandronate—Angiopathy—Prednisone—ankylosing spondylitis	0.000112	0.00155	CcSEcCtD
Ibandronate—Immune system disorder—Prednisone—ankylosing spondylitis	0.000111	0.00155	CcSEcCtD
Ibandronate—Malaise—Betamethasone—ankylosing spondylitis	0.000111	0.00154	CcSEcCtD
Ibandronate—Malaise—Dexamethasone—ankylosing spondylitis	0.000111	0.00154	CcSEcCtD
Ibandronate—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000111	0.00154	CcSEcCtD
Ibandronate—Vertigo—Dexamethasone—ankylosing spondylitis	0.000111	0.00154	CcSEcCtD
Ibandronate—Vertigo—Betamethasone—ankylosing spondylitis	0.000111	0.00154	CcSEcCtD
Ibandronate—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000111	0.00154	CcSEcCtD
Ibandronate—Infection—Triamcinolone—ankylosing spondylitis	0.00011	0.00153	CcSEcCtD
Ibandronate—Sweating—Methotrexate—ankylosing spondylitis	0.00011	0.00153	CcSEcCtD
Ibandronate—Infection—Methylprednisolone—ankylosing spondylitis	0.00011	0.00153	CcSEcCtD
Ibandronate—Shock—Triamcinolone—ankylosing spondylitis	0.000109	0.00152	CcSEcCtD
Ibandronate—Insomnia—Prednisolone—ankylosing spondylitis	0.000109	0.00152	CcSEcCtD
Ibandronate—Alopecia—Prednisone—ankylosing spondylitis	0.000109	0.00151	CcSEcCtD
Ibandronate—Shock—Methylprednisolone—ankylosing spondylitis	0.000109	0.00151	CcSEcCtD
Ibandronate—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000109	0.00151	CcSEcCtD
Ibandronate—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000108	0.00151	CcSEcCtD
Ibandronate—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000108	0.0015	CcSEcCtD
Ibandronate—Mental disorder—Prednisone—ankylosing spondylitis	0.000108	0.0015	CcSEcCtD
Ibandronate—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000107	0.00149	CcSEcCtD
Ibandronate—Erythema—Prednisone—ankylosing spondylitis	0.000107	0.00149	CcSEcCtD
Ibandronate—Malnutrition—Prednisone—ankylosing spondylitis	0.000107	0.00149	CcSEcCtD
Ibandronate—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000107	0.00149	CcSEcCtD
Ibandronate—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000107	0.00149	CcSEcCtD
Ibandronate—Hypertension—Dexamethasone—ankylosing spondylitis	0.000106	0.00148	CcSEcCtD
Ibandronate—Hypertension—Betamethasone—ankylosing spondylitis	0.000106	0.00148	CcSEcCtD
Ibandronate—Myalgia—Betamethasone—ankylosing spondylitis	0.000105	0.00146	CcSEcCtD
Ibandronate—Myalgia—Dexamethasone—ankylosing spondylitis	0.000105	0.00146	CcSEcCtD
Ibandronate—Anxiety—Dexamethasone—ankylosing spondylitis	0.000105	0.00145	CcSEcCtD
Ibandronate—Anxiety—Betamethasone—ankylosing spondylitis	0.000105	0.00145	CcSEcCtD
Ibandronate—Discomfort—Dexamethasone—ankylosing spondylitis	0.000104	0.00144	CcSEcCtD
Ibandronate—Discomfort—Betamethasone—ankylosing spondylitis	0.000104	0.00144	CcSEcCtD
Ibandronate—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000104	0.00144	CcSEcCtD
Ibandronate—Pain—Prednisolone—ankylosing spondylitis	0.000103	0.00143	CcSEcCtD
Ibandronate—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000103	0.00143	CcSEcCtD
Ibandronate—Pharyngitis—Methotrexate—ankylosing spondylitis	0.000102	0.00142	CcSEcCtD
Ibandronate—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000102	0.00141	CcSEcCtD
Ibandronate—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000101	0.0014	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000101	0.0014	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000101	0.0014	CcSEcCtD
Ibandronate—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000101	0.0014	CcSEcCtD
Ibandronate—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000101	0.0014	CcSEcCtD
Ibandronate—Insomnia—Triamcinolone—ankylosing spondylitis	0.0001	0.00139	CcSEcCtD
Ibandronate—Insomnia—Methylprednisolone—ankylosing spondylitis	0.0001	0.00139	CcSEcCtD
Ibandronate—Infection—Betamethasone—ankylosing spondylitis	9.99e-05	0.00139	CcSEcCtD
Ibandronate—Infection—Dexamethasone—ankylosing spondylitis	9.99e-05	0.00139	CcSEcCtD
Ibandronate—Ill-defined disorder—Prednisone—ankylosing spondylitis	9.96e-05	0.00138	CcSEcCtD
Ibandronate—Paraesthesia—Triamcinolone—ankylosing spondylitis	9.95e-05	0.00138	CcSEcCtD
Ibandronate—Feeling abnormal—Prednisolone—ankylosing spondylitis	9.93e-05	0.00138	CcSEcCtD
Ibandronate—Paraesthesia—Methylprednisolone—ankylosing spondylitis	9.93e-05	0.00138	CcSEcCtD
Ibandronate—Anaemia—Prednisone—ankylosing spondylitis	9.92e-05	0.00138	CcSEcCtD
Ibandronate—Shock—Dexamethasone—ankylosing spondylitis	9.9e-05	0.00138	CcSEcCtD
Ibandronate—Shock—Betamethasone—ankylosing spondylitis	9.9e-05	0.00138	CcSEcCtD
Ibandronate—Nervous system disorder—Dexamethasone—ankylosing spondylitis	9.86e-05	0.00137	CcSEcCtD
Ibandronate—Nervous system disorder—Betamethasone—ankylosing spondylitis	9.86e-05	0.00137	CcSEcCtD
Ibandronate—Angioedema—Prednisone—ankylosing spondylitis	9.81e-05	0.00136	CcSEcCtD
Ibandronate—Dyspepsia—Triamcinolone—ankylosing spondylitis	9.76e-05	0.00136	CcSEcCtD
Ibandronate—Dyspepsia—Methylprednisolone—ankylosing spondylitis	9.74e-05	0.00135	CcSEcCtD
Ibandronate—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	9.72e-05	0.00135	CcSEcCtD
Ibandronate—Hyperhidrosis—Betamethasone—ankylosing spondylitis	9.72e-05	0.00135	CcSEcCtD
Ibandronate—Malaise—Prednisone—ankylosing spondylitis	9.68e-05	0.00135	CcSEcCtD
Ibandronate—Vertigo—Prednisone—ankylosing spondylitis	9.64e-05	0.00134	CcSEcCtD
Ibandronate—Eye disorder—Methotrexate—ankylosing spondylitis	9.63e-05	0.00134	CcSEcCtD
Ibandronate—Urticaria—Prednisolone—ankylosing spondylitis	9.58e-05	0.00133	CcSEcCtD
Ibandronate—Cardiac disorder—Methotrexate—ankylosing spondylitis	9.56e-05	0.00133	CcSEcCtD
Ibandronate—Fatigue—Triamcinolone—ankylosing spondylitis	9.56e-05	0.00133	CcSEcCtD
Ibandronate—Fatigue—Methylprednisolone—ankylosing spondylitis	9.54e-05	0.00133	CcSEcCtD
Ibandronate—Pain—Triamcinolone—ankylosing spondylitis	9.48e-05	0.00132	CcSEcCtD
Ibandronate—Angiopathy—Methotrexate—ankylosing spondylitis	9.35e-05	0.0013	CcSEcCtD
Ibandronate—Immune system disorder—Methotrexate—ankylosing spondylitis	9.31e-05	0.00129	CcSEcCtD
Ibandronate—Mediastinal disorder—Methotrexate—ankylosing spondylitis	9.29e-05	0.00129	CcSEcCtD
Ibandronate—Hypertension—Prednisone—ankylosing spondylitis	9.27e-05	0.00129	CcSEcCtD
Ibandronate—Chills—Methotrexate—ankylosing spondylitis	9.25e-05	0.00128	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	9.16e-05	0.00127	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	9.16e-05	0.00127	CcSEcCtD
Ibandronate—Arthralgia—Prednisone—ankylosing spondylitis	9.14e-05	0.00127	CcSEcCtD
Ibandronate—Myalgia—Prednisone—ankylosing spondylitis	9.14e-05	0.00127	CcSEcCtD
Ibandronate—Feeling abnormal—Triamcinolone—ankylosing spondylitis	9.14e-05	0.00127	CcSEcCtD
Ibandronate—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	9.11e-05	0.00127	CcSEcCtD
Ibandronate—Anxiety—Prednisone—ankylosing spondylitis	9.11e-05	0.00127	CcSEcCtD
Ibandronate—Alopecia—Methotrexate—ankylosing spondylitis	9.11e-05	0.00127	CcSEcCtD
Ibandronate—Insomnia—Betamethasone—ankylosing spondylitis	9.1e-05	0.00126	CcSEcCtD
Ibandronate—Insomnia—Dexamethasone—ankylosing spondylitis	9.1e-05	0.00126	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	9.07e-05	0.00126	CcSEcCtD
Ibandronate—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	9.04e-05	0.00126	CcSEcCtD
Ibandronate—Paraesthesia—Dexamethasone—ankylosing spondylitis	9.03e-05	0.00126	CcSEcCtD
Ibandronate—Paraesthesia—Betamethasone—ankylosing spondylitis	9.03e-05	0.00126	CcSEcCtD
Ibandronate—Discomfort—Prednisone—ankylosing spondylitis	9.03e-05	0.00125	CcSEcCtD
Ibandronate—Mental disorder—Methotrexate—ankylosing spondylitis	9.03e-05	0.00125	CcSEcCtD
Ibandronate—Erythema—Methotrexate—ankylosing spondylitis	8.97e-05	0.00125	CcSEcCtD
Ibandronate—Malnutrition—Methotrexate—ankylosing spondylitis	8.97e-05	0.00125	CcSEcCtD
Ibandronate—Hypersensitivity—Prednisolone—ankylosing spondylitis	8.88e-05	0.00123	CcSEcCtD
Ibandronate—Dyspepsia—Dexamethasone—ankylosing spondylitis	8.85e-05	0.00123	CcSEcCtD
Ibandronate—Dyspepsia—Betamethasone—ankylosing spondylitis	8.85e-05	0.00123	CcSEcCtD
Ibandronate—Urticaria—Triamcinolone—ankylosing spondylitis	8.81e-05	0.00122	CcSEcCtD
Ibandronate—Urticaria—Methylprednisolone—ankylosing spondylitis	8.79e-05	0.00122	CcSEcCtD
Ibandronate—Dysgeusia—Methotrexate—ankylosing spondylitis	8.78e-05	0.00122	CcSEcCtD
Ibandronate—Body temperature increased—Triamcinolone—ankylosing spondylitis	8.76e-05	0.00122	CcSEcCtD
Ibandronate—Anaphylactic shock—Prednisone—ankylosing spondylitis	8.76e-05	0.00122	CcSEcCtD
Ibandronate—Abdominal pain—Methylprednisolone—ankylosing spondylitis	8.74e-05	0.00122	CcSEcCtD
Ibandronate—Decreased appetite—Dexamethasone—ankylosing spondylitis	8.74e-05	0.00122	CcSEcCtD
Ibandronate—Decreased appetite—Betamethasone—ankylosing spondylitis	8.74e-05	0.00122	CcSEcCtD
Ibandronate—Infection—Prednisone—ankylosing spondylitis	8.7e-05	0.00121	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	8.68e-05	0.00121	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	8.68e-05	0.00121	CcSEcCtD
Ibandronate—Back pain—Methotrexate—ankylosing spondylitis	8.68e-05	0.00121	CcSEcCtD
Ibandronate—Fatigue—Betamethasone—ankylosing spondylitis	8.67e-05	0.00121	CcSEcCtD
Ibandronate—Fatigue—Dexamethasone—ankylosing spondylitis	8.67e-05	0.00121	CcSEcCtD
Ibandronate—Shock—Prednisone—ankylosing spondylitis	8.62e-05	0.0012	CcSEcCtD
Ibandronate—Pain—Betamethasone—ankylosing spondylitis	8.6e-05	0.0012	CcSEcCtD
Ibandronate—Pain—Dexamethasone—ankylosing spondylitis	8.6e-05	0.0012	CcSEcCtD
Ibandronate—Nervous system disorder—Prednisone—ankylosing spondylitis	8.59e-05	0.00119	CcSEcCtD
Ibandronate—Skin disorder—Prednisone—ankylosing spondylitis	8.51e-05	0.00118	CcSEcCtD
Ibandronate—Hyperhidrosis—Prednisone—ankylosing spondylitis	8.47e-05	0.00118	CcSEcCtD
Ibandronate—Ill-defined disorder—Methotrexate—ankylosing spondylitis	8.32e-05	0.00116	CcSEcCtD
Ibandronate—Anaemia—Methotrexate—ankylosing spondylitis	8.29e-05	0.00115	CcSEcCtD
Ibandronate—Feeling abnormal—Betamethasone—ankylosing spondylitis	8.29e-05	0.00115	CcSEcCtD
Ibandronate—Feeling abnormal—Dexamethasone—ankylosing spondylitis	8.29e-05	0.00115	CcSEcCtD
Ibandronate—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	8.23e-05	0.00114	CcSEcCtD
Ibandronate—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	8.23e-05	0.00114	CcSEcCtD
Ibandronate—Hypersensitivity—Triamcinolone—ankylosing spondylitis	8.17e-05	0.00114	CcSEcCtD
Ibandronate—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	8.15e-05	0.00113	CcSEcCtD
Ibandronate—Malaise—Methotrexate—ankylosing spondylitis	8.09e-05	0.00112	CcSEcCtD
Ibandronate—Vertigo—Methotrexate—ankylosing spondylitis	8.06e-05	0.00112	CcSEcCtD
Ibandronate—Urticaria—Dexamethasone—ankylosing spondylitis	7.99e-05	0.00111	CcSEcCtD
Ibandronate—Urticaria—Betamethasone—ankylosing spondylitis	7.99e-05	0.00111	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	7.98e-05	0.00111	CcSEcCtD
Ibandronate—Dizziness—Prednisolone—ankylosing spondylitis	7.97e-05	0.00111	CcSEcCtD
Ibandronate—Asthenia—Triamcinolone—ankylosing spondylitis	7.95e-05	0.00111	CcSEcCtD
Ibandronate—Body temperature increased—Betamethasone—ankylosing spondylitis	7.95e-05	0.00111	CcSEcCtD
Ibandronate—Abdominal pain—Dexamethasone—ankylosing spondylitis	7.95e-05	0.00111	CcSEcCtD
Ibandronate—Body temperature increased—Dexamethasone—ankylosing spondylitis	7.95e-05	0.00111	CcSEcCtD
Ibandronate—Abdominal pain—Betamethasone—ankylosing spondylitis	7.95e-05	0.00111	CcSEcCtD
Ibandronate—Asthenia—Methylprednisolone—ankylosing spondylitis	7.94e-05	0.0011	CcSEcCtD
Ibandronate—Insomnia—Prednisone—ankylosing spondylitis	7.92e-05	0.0011	CcSEcCtD
Ibandronate—Paraesthesia—Prednisone—ankylosing spondylitis	7.87e-05	0.00109	CcSEcCtD
Ibandronate—Pruritus—Triamcinolone—ankylosing spondylitis	7.84e-05	0.00109	CcSEcCtD
Ibandronate—Pruritus—Methylprednisolone—ankylosing spondylitis	7.83e-05	0.00109	CcSEcCtD
Ibandronate—Dyspepsia—Prednisone—ankylosing spondylitis	7.71e-05	0.00107	CcSEcCtD
Ibandronate—Arthralgia—Methotrexate—ankylosing spondylitis	7.64e-05	0.00106	CcSEcCtD
Ibandronate—Myalgia—Methotrexate—ankylosing spondylitis	7.64e-05	0.00106	CcSEcCtD
Ibandronate—Chest pain—Methotrexate—ankylosing spondylitis	7.64e-05	0.00106	CcSEcCtD
Ibandronate—Decreased appetite—Prednisone—ankylosing spondylitis	7.61e-05	0.00106	CcSEcCtD
Ibandronate—Rash—Prednisolone—ankylosing spondylitis	7.6e-05	0.00106	CcSEcCtD
Ibandronate—Dermatitis—Prednisolone—ankylosing spondylitis	7.59e-05	0.00106	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	7.58e-05	0.00105	CcSEcCtD
Ibandronate—Diarrhoea—Methylprednisolone—ankylosing spondylitis	7.57e-05	0.00105	CcSEcCtD
Ibandronate—Fatigue—Prednisone—ankylosing spondylitis	7.55e-05	0.00105	CcSEcCtD
Ibandronate—Headache—Prednisolone—ankylosing spondylitis	7.55e-05	0.00105	CcSEcCtD
Ibandronate—Discomfort—Methotrexate—ankylosing spondylitis	7.55e-05	0.00105	CcSEcCtD
Ibandronate—Constipation—Prednisone—ankylosing spondylitis	7.49e-05	0.00104	CcSEcCtD
Ibandronate—Dizziness—Triamcinolone—ankylosing spondylitis	7.33e-05	0.00102	CcSEcCtD
Ibandronate—Anaphylactic shock—Methotrexate—ankylosing spondylitis	7.32e-05	0.00102	CcSEcCtD
Ibandronate—Dizziness—Methylprednisolone—ankylosing spondylitis	7.31e-05	0.00102	CcSEcCtD
Ibandronate—Infection—Methotrexate—ankylosing spondylitis	7.27e-05	0.00101	CcSEcCtD
Ibandronate—Feeling abnormal—Prednisone—ankylosing spondylitis	7.22e-05	0.001	CcSEcCtD
Ibandronate—Asthenia—Dexamethasone—ankylosing spondylitis	7.22e-05	0.001	CcSEcCtD
Ibandronate—Asthenia—Betamethasone—ankylosing spondylitis	7.22e-05	0.001	CcSEcCtD
Ibandronate—Nervous system disorder—Methotrexate—ankylosing spondylitis	7.18e-05	0.000998	CcSEcCtD
Ibandronate—Gastrointestinal pain—Prednisone—ankylosing spondylitis	7.16e-05	0.000995	CcSEcCtD
Ibandronate—Nausea—Prednisolone—ankylosing spondylitis	7.16e-05	0.000995	CcSEcCtD
Ibandronate—Pruritus—Dexamethasone—ankylosing spondylitis	7.12e-05	0.000989	CcSEcCtD
Ibandronate—Pruritus—Betamethasone—ankylosing spondylitis	7.12e-05	0.000989	CcSEcCtD
Ibandronate—Skin disorder—Methotrexate—ankylosing spondylitis	7.11e-05	0.000988	CcSEcCtD
Ibandronate—Hyperhidrosis—Methotrexate—ankylosing spondylitis	7.08e-05	0.000984	CcSEcCtD
Ibandronate—Vomiting—Triamcinolone—ankylosing spondylitis	7.05e-05	0.00098	CcSEcCtD
Ibandronate—Vomiting—Methylprednisolone—ankylosing spondylitis	7.03e-05	0.000977	CcSEcCtD
Ibandronate—Rash—Triamcinolone—ankylosing spondylitis	6.99e-05	0.000971	CcSEcCtD
Ibandronate—Dermatitis—Triamcinolone—ankylosing spondylitis	6.98e-05	0.00097	CcSEcCtD
Ibandronate—Rash—Methylprednisolone—ankylosing spondylitis	6.97e-05	0.000969	CcSEcCtD
Ibandronate—Dermatitis—Methylprednisolone—ankylosing spondylitis	6.97e-05	0.000968	CcSEcCtD
Ibandronate—Urticaria—Prednisone—ankylosing spondylitis	6.96e-05	0.000967	CcSEcCtD
Ibandronate—Headache—Triamcinolone—ankylosing spondylitis	6.94e-05	0.000965	CcSEcCtD
Ibandronate—Headache—Methylprednisolone—ankylosing spondylitis	6.93e-05	0.000963	CcSEcCtD
Ibandronate—Abdominal pain—Prednisone—ankylosing spondylitis	6.92e-05	0.000962	CcSEcCtD
Ibandronate—Body temperature increased—Prednisone—ankylosing spondylitis	6.92e-05	0.000962	CcSEcCtD
Ibandronate—Diarrhoea—Dexamethasone—ankylosing spondylitis	6.88e-05	0.000956	CcSEcCtD
Ibandronate—Diarrhoea—Betamethasone—ankylosing spondylitis	6.88e-05	0.000956	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	6.67e-05	0.000927	CcSEcCtD
Ibandronate—Dizziness—Betamethasone—ankylosing spondylitis	6.65e-05	0.000924	CcSEcCtD
Ibandronate—Dizziness—Dexamethasone—ankylosing spondylitis	6.65e-05	0.000924	CcSEcCtD
Ibandronate—Insomnia—Methotrexate—ankylosing spondylitis	6.62e-05	0.00092	CcSEcCtD
Ibandronate—Nausea—Triamcinolone—ankylosing spondylitis	6.58e-05	0.000915	CcSEcCtD
Ibandronate—Paraesthesia—Methotrexate—ankylosing spondylitis	6.57e-05	0.000914	CcSEcCtD
Ibandronate—Nausea—Methylprednisolone—ankylosing spondylitis	6.57e-05	0.000913	CcSEcCtD
Ibandronate—Hypersensitivity—Prednisone—ankylosing spondylitis	6.45e-05	0.000897	CcSEcCtD
Ibandronate—Dyspepsia—Methotrexate—ankylosing spondylitis	6.44e-05	0.000896	CcSEcCtD
Ibandronate—Vomiting—Betamethasone—ankylosing spondylitis	6.4e-05	0.000889	CcSEcCtD
Ibandronate—Vomiting—Dexamethasone—ankylosing spondylitis	6.4e-05	0.000889	CcSEcCtD
Ibandronate—Decreased appetite—Methotrexate—ankylosing spondylitis	6.36e-05	0.000884	CcSEcCtD
Ibandronate—Rash—Dexamethasone—ankylosing spondylitis	6.34e-05	0.000881	CcSEcCtD
Ibandronate—Rash—Betamethasone—ankylosing spondylitis	6.34e-05	0.000881	CcSEcCtD
Ibandronate—Dermatitis—Betamethasone—ankylosing spondylitis	6.34e-05	0.000881	CcSEcCtD
Ibandronate—Dermatitis—Dexamethasone—ankylosing spondylitis	6.34e-05	0.000881	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	6.32e-05	0.000878	CcSEcCtD
Ibandronate—Fatigue—Methotrexate—ankylosing spondylitis	6.31e-05	0.000877	CcSEcCtD
Ibandronate—Headache—Dexamethasone—ankylosing spondylitis	6.3e-05	0.000876	CcSEcCtD
Ibandronate—Headache—Betamethasone—ankylosing spondylitis	6.3e-05	0.000876	CcSEcCtD
Ibandronate—Asthenia—Prednisone—ankylosing spondylitis	6.28e-05	0.000873	CcSEcCtD
Ibandronate—Pain—Methotrexate—ankylosing spondylitis	6.26e-05	0.00087	CcSEcCtD
Ibandronate—Pruritus—Prednisone—ankylosing spondylitis	6.2e-05	0.000861	CcSEcCtD
Ibandronate—Feeling abnormal—Methotrexate—ankylosing spondylitis	6.03e-05	0.000838	CcSEcCtD
Ibandronate—Diarrhoea—Prednisone—ankylosing spondylitis	5.99e-05	0.000833	CcSEcCtD
Ibandronate—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	5.99e-05	0.000832	CcSEcCtD
Ibandronate—Nausea—Dexamethasone—ankylosing spondylitis	5.97e-05	0.00083	CcSEcCtD
Ibandronate—Nausea—Betamethasone—ankylosing spondylitis	5.97e-05	0.00083	CcSEcCtD
Ibandronate—Urticaria—Methotrexate—ankylosing spondylitis	5.82e-05	0.000808	CcSEcCtD
Ibandronate—Dizziness—Prednisone—ankylosing spondylitis	5.79e-05	0.000805	CcSEcCtD
Ibandronate—Abdominal pain—Methotrexate—ankylosing spondylitis	5.79e-05	0.000804	CcSEcCtD
Ibandronate—Body temperature increased—Methotrexate—ankylosing spondylitis	5.79e-05	0.000804	CcSEcCtD
Ibandronate—Vomiting—Prednisone—ankylosing spondylitis	5.57e-05	0.000774	CcSEcCtD
Ibandronate—Rash—Prednisone—ankylosing spondylitis	5.52e-05	0.000768	CcSEcCtD
Ibandronate—Dermatitis—Prednisone—ankylosing spondylitis	5.52e-05	0.000767	CcSEcCtD
Ibandronate—Headache—Prednisone—ankylosing spondylitis	5.49e-05	0.000763	CcSEcCtD
Ibandronate—Hypersensitivity—Methotrexate—ankylosing spondylitis	5.39e-05	0.00075	CcSEcCtD
Ibandronate—Asthenia—Methotrexate—ankylosing spondylitis	5.25e-05	0.00073	CcSEcCtD
Ibandronate—Nausea—Prednisone—ankylosing spondylitis	5.2e-05	0.000723	CcSEcCtD
Ibandronate—Pruritus—Methotrexate—ankylosing spondylitis	5.18e-05	0.00072	CcSEcCtD
Ibandronate—Diarrhoea—Methotrexate—ankylosing spondylitis	5.01e-05	0.000696	CcSEcCtD
Ibandronate—Dizziness—Methotrexate—ankylosing spondylitis	4.84e-05	0.000673	CcSEcCtD
Ibandronate—Vomiting—Methotrexate—ankylosing spondylitis	4.65e-05	0.000647	CcSEcCtD
Ibandronate—Rash—Methotrexate—ankylosing spondylitis	4.62e-05	0.000641	CcSEcCtD
Ibandronate—Dermatitis—Methotrexate—ankylosing spondylitis	4.61e-05	0.000641	CcSEcCtD
Ibandronate—Headache—Methotrexate—ankylosing spondylitis	4.59e-05	0.000637	CcSEcCtD
Ibandronate—Nausea—Methotrexate—ankylosing spondylitis	4.35e-05	0.000604	CcSEcCtD
